Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | EDNRA | P25101 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | ITGAV | P06756 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4673967 | 1.00 | KMT2A (0.59) | KMT2AMAPK9ITGB3ITGA2BALDH1A1 | |
| SCHEMBL31295300 | 1.00 | KMT2A (0.59) | KMT2AMAPK9ITGB3ITGA2BALDH1A1 | |
| SCHEMBL5150990 | 1.00 | KMT2A (0.59) | KMT2AMAPK9ITGB3ITGA2BALDH1A1 | |
| Hydrochloric Acid SCHEMBL7976302 | 0.98 | KMT2A (0.58) | KMT2AMAPK9ITGB3ITGA2BALDH1A1 | |
| Hydrochloric Acid SCHEMBL6755379 | 0.98 | KMT2A (0.58) | KMT2AMAPK9ITGB3ITGA2BALDH1A1 | |
| Hydrochloric Acid SCHEMBL5148928 | 0.98 | KMT2A (0.58) | KMT2AMAPK9ITGB3ITGA2BALDH1A1 | |
| SCHEMBL7100421 | 0.91 | PTGS1 (0.56) | KMT2AMAPK9ALDH1A1MAPK1CYP1A2 | |
| SCHEMBL4179129 | 0.91 | PTGS1 (0.56) | KMT2AMAPK9ALDH1A1MAPK1CYP1A2 | |
| Leucine SCHEMBL27542716 | 0.87 | KMT2A (0.51) | KMT2AMAPK9ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL20545862 | 0.85 | CTSA (0.53) | KMT2AMAPK9PTGS2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014752-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-01-19 | — | — | US | claimed |
| US-20030114441-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2003-06-19 | — | — | US | claimed |
| EP-3480187-B1 | METHOD FOR PREPARING INDENOISOQUINOLINE DERIVATIVES | UNIV NAT TAIWAN NORMAL (TW) | 2023-10-04 | — | — | EP | disclosed |
| US-10336704-B2 | Method for preparing indenoisoquinoline derivatives | NATIONAL TAIWAN NORMAL UNIVERSITY (TW) | 2019-07-02 | — | — | US | disclosed |
| US-20190127330-A1 | Method for Preparing Indenoisoquinoline Derivatives | NATIONAL TAIWAN NORMAL UNIVERSITY (TW) | 2019-05-02 | — | — | US | disclosed |
| CN-109134481-A | A kind of substituted azole chromogen ketone compounds or its pharmaceutically acceptable salt and its preparation method and application | 中山大学 | 2019-01-04 | — | — | CN | disclosed |
| US-20130245283-A1 | THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS | ALLERGAN, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20100280250-A1 | THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS | ALLERGAN, INC. | 2010-11-04 | — | — | US | disclosed |
| CN-101454281-A | Prostaglandin ep4 agonists | ALLERGAN INC (US) | 2009-06-10 | — | — | CN | disclosed |
| EP-2027085-A1 | PROSTAGLANDIN EP4 AGONISTS | Allergan, Inc. (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007115001-A1 | PROSTAGLANDIN EP4 AGONISTS | ALLERGAN, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-6521654-B2 | For therapy and prophylaxis of rheumatoid arthritis, or of allergic disorders, asthma, inflammation; inhibitors of the adhesion and migration of leucocytes and/or antagonists of adhesion receptor VLA-4 belonging to the integrins group | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-02-18 | — | — | US | disclosed |
| US-20020143043-A1 | Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-10-03 | — | — | US | disclosed |
| US-6331552-B1 | THERAPY AND PROPHYLAXIS OF INFLAMMATORY DISORDERS, FOR EXAMPLE OF RHEUMATOID ARTHRITIS, OR OF ALLERGIC DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-12-18 | — | — | US | disclosed |
| EP-1098878-A1 | BISPIPERIDINES AS ANTITHROMBOTIC AGENTS | LABORATOIRE L. LAFON (FR) | 2001-05-16 | — | — | EP | disclosed |
| EP-1098888-A1 | PIPERAZINONE DERIVATIVES AND THEIR USES | LABORATOIRE L. LAFON (FR) | 2001-05-16 | — | — | EP | disclosed |
| US-6096773-A | INHIBITOR OF BINDING OF INTEGRIN TO ITS RECEPTORS, SUCH AS (VASCULAR CELL ADHESION MOLECULE-1) AND FIBRONECTIN AND USEFUL FOR CONTROLLING THE DISEASES INDUCED BY BINDING | TEXAS BIOTECHNOLOGY CORPORATION, INC. (US) | 2000-08-01 | — | — | US | disclosed |
| WO-2000003986-A1 | BISPIPERIDINES AS ANTITHROMBOTIC AGENTS | LABORATOIRE L. LAFON (FR) | 2000-01-27 | — | — | WO | disclosed |
| WO-2000004000-A1 | PIPERAZINONE DERIVATIVES AND THEIR USES | LABORATOIRE L. LAFON (FR) | 2000-01-27 | — | — | WO | disclosed |
| EP-0918059-A1 | Substituted imidazoline derivatives, their preparation, their use, and pharmaceutical compositions containing them | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143043-A1 | Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them | VCAM1, ITGA1, ITGA4 | KMT2A 1038/4885MAPK9 607/4885ITGB3 10/4885 |
| US-20030114441-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | CA3, GAP43, SLC1A2 | KMT2A 1196/4885MAPK9 3825/4885ITGB3 4336/4885 |
| US-20060014752-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | GAP43, GABRE, CA3 | KMT2A 1592/4885MAPK9 3670/4885ITGB3 3768/4885 |
| US-20130245283-A1 | THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS | PTGER4, PTGER1, PTGER3 | KMT2A 3669/4885MAPK9 3814/4885ITGB3 1771/4885 |
| US-10336704-B2 | Method for preparing indenoisoquinoline derivatives | CYP1A2, RECQL, RDX | KMT2A 477/4885MAPK9 2694/4885ITGB3 3584/4885 |
| US-20190127330-A1 | Method for Preparing Indenoisoquinoline Derivatives | CYP1A2, RECQL, RDX | KMT2A 477/4885MAPK9 2694/4885ITGB3 3584/4885 |
| US-20100280250-A1 | THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS | PTGER4, PTGER1, PTGER3 | KMT2A 3669/4885MAPK9 3814/4885ITGB3 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.